Venlafaxine (Effexor XR)
venlafaxine hydrochloride extended-release
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Major Depressive Disorder (MDD) | Adults | Monotherapy | FDA Approved |
| Generalized Anxiety Disorder (GAD) | Adults | Monotherapy | FDA Approved |
| Social Anxiety Disorder (SAD) | Adults | Monotherapy | FDA Approved |
| Panic Disorder (PD) | Adults | Monotherapy (with or without agoraphobia) | FDA Approved |
Venlafaxine is an SNRI with four FDA-approved indications in adults. Its dual serotonin and norepinephrine reuptake inhibition distinguishes it from SSRIs, with the noradrenergic component becoming clinically relevant at higher doses (typically ≥150 mg/day). The extended-release formulation (Effexor XR) is the predominantly prescribed form, offering once-daily dosing and improved tolerability compared to the immediate-release tablets. Venlafaxine is not approved for paediatric use.
Diabetic neuropathic pain: Studied at 150–225 mg/day; guideline-recommended. Evidence quality: High.
Fibromyalgia: Evidence quality: Moderate (RCTs).
Migraine prophylaxis: Used at 75–150 mg/day. Evidence quality: Moderate.
Vasomotor symptoms (menopause): 37.5–150 mg/day. Evidence quality: High (multiple RCTs).
PTSD: Evidence quality: Moderate (RCTs).
ADHD (adjunctive): Evidence quality: Low.
Dosing
Adult Dosing by Clinical Scenario (Effexor XR)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Major depression — initial treatment | 75 mg once daily | 75 mg/day | 225 mg/day | Some patients may start at 37.5 mg/day for 4–7 days before increasing to 75 mg. Increase by up to 75 mg at ≥4-day intervals Noradrenergic effects become prominent at ≥150 mg/day |
| Generalized anxiety disorder | 75 mg once daily | 75 mg/day | 225 mg/day | 37.5 mg/day for 4–7 days may be used initially. Increase by up to 75 mg at ≥4-day intervals 75 mg effective for many patients |
| Social anxiety disorder | 75 mg once daily | 75 mg/day | 75 mg/day | No evidence that higher doses confer additional benefit Flat dose-response in clinical trials |
| Panic disorder | 37.5 mg once daily | 75 mg/day | 225 mg/day | Start low to avoid initial panic exacerbation. Increase by up to 75 mg at ≥7-day intervals Slower titration than MDD/GAD |
Special Population Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Hepatic impairment (mild–moderate) | Reduce total daily dose by 50% | Individualise | Individualise | Child-Pugh A/B: bioavailability increased 2–3 fold, t½ doubled, clearance reduced >50% Severe (Child-Pugh C) or cirrhosis: reduce ≥50% |
| Renal impairment (mild–moderate) | Reduce total daily dose by 25–50% | Individualise | Individualise | Severe (CrCl <30 mL/min) or dialysis: reduce ≥50%. Dialysis: t½ prolonged ~180% High intersubject variability; individualise |
| Elderly patients | Standard dosing | Standard | 225 mg/day | No dose adjustment for age alone; exercise caution and consider renal/hepatic function Higher hyponatraemia risk in elderly |
At least 14 days must elapse between stopping an MAOI and starting venlafaxine. However, only 7 days must elapse after stopping venlafaxine before starting an MAOI (shorter than the 14-day SSRI requirement, reflecting venlafaxine’s shorter half-life). In clinical studies, tapering was achieved by reducing the daily dose by 75 mg at one-week intervals; some patients may require several months to discontinue.
At lower doses (37.5–75 mg/day), venlafaxine acts predominantly as a serotonin reuptake inhibitor. At 150 mg/day and above, norepinephrine reuptake inhibition becomes clinically significant. This dual mechanism can be leveraged therapeutically: patients with anhedonia, fatigue, or cognitive symptoms may benefit from doses in the 150–225 mg range where noradrenergic effects augment the serotonergic action. The dose-dependent blood pressure elevation parallels this noradrenergic activity.
Pharmacology
Mechanism of Action
Venlafaxine and its major active metabolite, O-desmethylvenlafaxine (ODV, also known as desvenlafaxine), are potent and selective inhibitors of both serotonin (5-HT) and norepinephrine (NE) neuronal reuptake, with weak inhibition of dopamine reuptake. Neither venlafaxine nor ODV has significant affinity for muscarinic cholinergic, histamine H1, or α1-adrenergic receptors, and neither possesses MAO inhibitory activity. This clean receptor profile translates to fewer anticholinergic, sedative, and cardiovascular side effects compared to tricyclic antidepressants. ODV (marketed separately as desvenlafaxine) is equipotent to the parent compound and contributes substantially to the overall pharmacological effect. Venlafaxine is a relatively weak inhibitor of CYP2D6 and does not significantly inhibit CYP1A2, CYP2C9, or CYP2C19.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Well absorbed (≥92%); bioavailability ~45% due to extensive first-pass metabolism to ODV; food does not affect bioavailability; Effexor XR: steady state in 3 days; linear PK over 75–450 mg/day | Once-daily dosing with food; predictable dose-exposure relationship; can be taken morning or evening |
| Distribution | Vd 7.5 ± 3.7 L/kg (venlafaxine), 5.7 ± 1.8 L/kg (ODV); protein binding 27% (venlafaxine), 30% (ODV) | Very low protein binding — negligible displacement interactions; no dose adjustment needed when co-prescribing highly protein-bound drugs |
| Metabolism | Extensive hepatic first-pass via CYP2D6 (primary, to ODV) and CYP3A4 (minor, to N-desmethylvenlafaxine); ODV is equipotent and the predominant circulating active species; weak CYP2D6 inhibitor; CYP2D6 PM status alters parent:metabolite ratio but total active moiety unchanged | CYP2D6 inhibitors shift the ratio toward venlafaxine but do not significantly change total active compound levels — no routine dose adjustment needed; CYP3A4 inhibitors increase both venlafaxine and ODV levels |
| Elimination | t½: venlafaxine 5 ± 2 h, ODV 11 ± 2 h; clearance 1.3 ± 0.6 L/h/kg (venlafaxine), 0.4 ± 0.2 L/h/kg (ODV); ~87% recovered in urine within 48 h (5% as parent, 29% as unconjugated ODV, 26% as conjugated ODV, 27% as minor metabolites) | ODV drives the effective half-life (~11 h); discontinuation syndrome risk is substantial due to combined short half-lives; hepatic cirrhosis: venlafaxine t½ prolonged 30%, clearance −50%; dialysis: t½ prolonged ~180% |
Side Effects
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nausea | 30.0% vs 11.8% placebo | Most common AE; dose-related; usually improves within 1–2 weeks; taking with food helps |
| Insomnia | 17.8% vs 9.5% placebo | Noradrenergic effect; consider morning dosing |
| Dizziness | 15.8% vs 9.5% placebo | Usually transient; caution with postural changes |
| Somnolence | 15.3% vs 7.5% placebo | Paradoxical given insomnia; both occur; may reflect different patient subgroups |
| Dry mouth | 14.8% vs 5.3% placebo | Despite minimal muscarinic affinity; encourage oral hygiene |
| Asthenia | 12.6% vs 7.8% placebo | Usually improves over time |
| Sweating | 11.4% vs 2.9% placebo | Noradrenergic effect; may persist; includes night sweats |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Abnormal ejaculation/orgasm (males) | 9.9% vs 0.5% placebo | Primarily delayed ejaculation; significant and common; discuss proactively |
| Anorexia | 9.8% vs 2.6% placebo | May lead to weight loss; monitor weight |
| Constipation | 9.3% vs 3.4% placebo | Noradrenergic effect; manage with fibre and fluids |
| Diarrhoea | 7.7% vs 7.2% placebo | Minimally above placebo |
| Nervousness | 7.1% vs 5.0% placebo | More common early in treatment; may represent activation |
| Impotence (males) | 5.3% vs 1.0% placebo | Discuss management strategies proactively |
| Libido decreased | 5.1% vs 1.6% placebo | Both sexes; likely underreported |
| Tremor | 4.7% vs 1.6% placebo | Fine postural tremor; dose-related |
| Vomiting | 4.3% vs 2.7% placebo | Usually early and transient |
| Abnormal vision | 4.2% vs 1.6% placebo | Includes blurred vision, mydriasis |
| Yawn | 3.7% vs 0.2% placebo | Serotonergic effect; benign |
| Vasodilatation | 3.7% vs 1.9% placebo | Includes flushing; usually self-limiting |
| Anorgasmia (males) | 3.6% vs 0.1% placebo | Enquire proactively |
| Hypertension | 3.4% vs 2.6% placebo | Dose-dependent; see sustained BP elevation data below |
| Abnormal dreams | 2.9% vs 1.4% placebo | More vivid or disturbing dreams |
| Paresthesia | 2.4% vs 1.4% placebo | Also a prominent discontinuation symptom |
| Palpitation | 2.2% vs 2.0% placebo | Marginally above placebo; mean pulse increase 1–3 bpm |
| Anorgasmia (females) | 2.0% vs 0.2% placebo | Likely underreported |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Sustained hypertension | MDD 3.0%; GAD 0.5%; SAD 0.6%; PD 0.9% (sustained SDBP ≥90 mmHg) | Dose-dependent; can occur at any time | Monitor BP before and regularly during treatment; dose reduction or discontinuation for sustained elevation |
| Suicidal thoughts/behaviours | 14 per 1,000 (<18 y); 5 per 1,000 (18–24 y) | First weeks to months | Close monitoring at initiation and dose changes |
| Serotonin syndrome | Rare | Hours to days, especially with co-serotonergic drugs | Discontinue all serotonergic agents; supportive care |
| Hyponatraemia (SIADH) | Uncommon; Na <110 mmol/L reported | Days to weeks; elderly at higher risk | Check sodium; discontinue; medical management |
| Mania/hypomania | MDD 0.3%; SAD 0.2%; PD 0.1% | Days to weeks | Discontinue; psychiatric reassessment |
| Seizures | Reported (not systematically evaluated) | Any time | Use cautiously in seizure disorders |
| Interstitial lung disease / eosinophilic pneumonia | Rare | Variable; progressive dyspnoea, cough | Prompt medical evaluation; consider discontinuation |
| Stevens-Johnson syndrome / TEN | Very rare (postmarketing) | Days to weeks | Immediate discontinuation; dermatology referral |
| Takotsubo cardiomyopathy | Very rare (postmarketing) | Variable | Cardiology evaluation; consider discontinuation |
Venlafaxine causes dose-related blood pressure elevation, driven by noradrenergic activity. In premarketing studies, 1.4% of patients had a ≥15 mmHg increase in supine diastolic BP to ≥105 mmHg (vs 0.9% placebo), and 1.0% had a ≥20 mmHg increase in supine systolic BP to ≥180 mmHg (vs 0.3% placebo). Sustained hypertension (SDBP ≥90 mmHg and ≥10 mmHg above baseline for 3 consecutive visits) occurred in up to 3% of MDD patients. Pre-existing hypertension must be controlled before initiation. Regular BP monitoring is required throughout treatment. Venlafaxine also increases mean serum cholesterol (by +1.5 to +7.9 mg/dL across indications vs decreases for placebo) and triglycerides, warranting lipid monitoring with long-term use.
Drug Interactions
Venlafaxine is metabolised primarily by CYP2D6 to its active metabolite ODV, with CYP3A4 as a secondary pathway. Importantly, because both parent and metabolite are pharmacologically active, CYP2D6 inhibition shifts the ratio but does not significantly alter total active moiety exposure. Venlafaxine is a weak CYP2D6 inhibitor and does not significantly inhibit CYP1A2, CYP2C9, or CYP2C19, giving it a cleaner interaction profile than SSRIs like fluvoxamine, fluoxetine, or paroxetine. The primary interaction concerns are pharmacodynamic: serotonin syndrome risk with co-serotonergic drugs, and blood pressure effects with noradrenergic agents.
Monitoring
- Blood PressureBaseline, then regularly during treatment
RoutineMost important monitoring parameter. Dose-related increases occur. Control pre-existing hypertension before starting. Consider dose reduction or discontinuation for sustained elevations - Mood & SuicidalityWeekly for 4 weeks, biweekly for 8 weeks, then per judgement
RoutineEspecially in patients <25 years. Monitor at dose changes - Lipid PanelBaseline, then periodically with long-term use
RoutineVenlafaxine increases cholesterol (+1.5 to +7.9 mg/dL) and triglycerides; 5.3% of patients had clinically relevant increases in long-term studies - Sexual FunctionBaseline, then each visit
RoutineEjaculatory dysfunction 9.9% (males), impotence 5.3%, libido decrease 5.1%; enquire proactively - WeightBaseline, then every 3–6 months
RoutineAnorexia in 9.8%; weight loss more common than gain; monitor paediatric patients closely if used off-label - Sodium (Na+)Baseline in at-risk; recheck 2–4 weeks
Trigger-basedAt-risk: elderly, diuretic users. Na <110 mmol/L reported - Discontinuation SymptomsDuring and after any dose reduction
RoutineVenlafaxine has one of the highest discontinuation syndrome rates; taper by 75 mg/week. Monitor for dizziness, electric shock sensations, nausea, irritability, nightmares - Respiratory SymptomsIf dyspnoea, cough, or chest discomfort develop
Trigger-basedRare interstitial lung disease and eosinophilic pneumonia reported; prompt evaluation needed
Contraindications & Cautions
Absolute Contraindications
- Known hypersensitivity to venlafaxine, desvenlafaxine, or any excipient (anaphylaxis, angioedema reported)
- Concurrent MAOI use or within 14 days of stopping an MAOI (linezolid, IV methylene blue included); allow 7 days after stopping venlafaxine before starting MAOI
Relative Contraindications (Specialist Input Recommended)
- Uncontrolled hypertension — control BP before initiation; dose-related BP elevation makes venlafaxine particularly risky in this population
- Unstable cardiovascular disease or recent MI — systematically excluded from premarketing trials; BP and heart rate effects are concerning
- Undiagnosed bipolar disorder — mania/hypomania risk 0.1–0.3%; screen before starting
Use with Caution
- Seizure disorders — seizures reported; not systematically evaluated in epilepsy
- Anatomically narrow angles (untreated) — angle-closure glaucoma risk
- Hepatic impairment — reduce dose 50% (mild–moderate); ≥50% (severe/cirrhosis)
- Renal impairment — reduce 25–50% (mild–moderate); ≥50% (severe/dialysis)
- Elderly — no age-based adjustment but higher hyponatraemia risk; consider renal/hepatic function
- Late pregnancy — neonatal poor adaptation syndrome; based on animal data, may cause fetal harm
- Breastfeeding — venlafaxine and ODV excreted in breast milk
Antidepressants increased the risk of suicidal thinking and behaviour in paediatric and young adult patients in short-term studies. The risk is highest in those under 18 (14 additional cases per 1,000 treated) and 18–24 year olds (5 additional per 1,000). Effexor XR is not approved for paediatric use. All patients started on antidepressant therapy should be closely monitored for clinical worsening and suicidal thoughts, especially during initial months and at dose changes.
Patient Counselling
Purpose of Therapy
Venlafaxine works by increasing both serotonin and norepinephrine levels in the brain. It is used to treat depression, generalised anxiety, social anxiety, and panic disorder. Full benefit may take 2–6 weeks to develop.
How to Take
Take Effexor XR once daily with food at approximately the same time each day. Swallow capsules whole — do not crush, chew, or open them. If you cannot swallow capsules, they may be opened and sprinkled on applesauce (swallow immediately without chewing).
Sources
- EFFEXOR XR (venlafaxine extended-release) capsules. Full Prescribing Information. Viatris Pharmaceuticals Inc. Revised August 2023. FDA LabelPrimary regulatory source for all dosing, adverse reaction incidence rates, blood pressure data, contraindications, and pharmacokinetics.
- EFFEXOR (venlafaxine hydrochloride) tablets. Full Prescribing Information. FDA Label (IR)Immediate-release formulation PI; cross-referenced for PK interaction studies (cimetidine, diazepam, metoprolol, ketoconazole) and hepatic/renal impairment data.
- Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178:234–241. DOIPooled analysis demonstrating higher remission rates with venlafaxine vs SSRIs in MDD, supporting its use as a step-up option.
- Gelenberg AJ, Lydiard RB, Rudolph RL, et al. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA. 2000;283(23):3082–3088. DOIPivotal 6-month GAD trial demonstrating sustained efficacy and relapse prevention.
- Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry. 2005;62(2):190–198. DOIHead-to-head comparison demonstrating venlafaxine XR efficacy equivalent to paroxetine in SAD.
- Bradwejn J, Ahokas A, Stein DJ, et al. Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry. 2005;187:352–359. DOIPivotal panic disorder trial supporting FDA approval for this indication.
- Lam RW, Kennedy SH, Adams C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults. Can J Psychiatry. 2024;69(9):641–687. DOIMost recent CANMAT update recommending venlafaxine XR as first-line pharmacotherapy for MDD.
- Bandelow B, Allgulander C, Baldwin DS, et al. WFSBP guidelines for treatment of anxiety, OCD, and PTSD — Version 3. World J Biol Psychiatry. 2023;24(2):79–117. DOIInternational guideline recommending venlafaxine as first-line for GAD, SAD, and panic disorder.
- National Institute for Health and Care Excellence (NICE). Depression in adults: treatment and management. NICE guideline NG222. 2022. NICEUK guideline including venlafaxine among first-line antidepressant options with specific guidance on blood pressure monitoring.
- Muth EA, Haskins JT, Moyer JA, et al. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol. 1986;35(24):4493–4497. DOIOriginal characterisation of venlafaxine’s dual serotonin-norepinephrine reuptake inhibition mechanism.
- Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs. Lancet. 2018;391(10128):1357–1366. DOINetwork meta-analysis positioning venlafaxine among the most efficacious antidepressants, with moderate acceptability.
- Klamerus KJ, Maloney K, Rudolph RL, et al. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol. 1992;32(8):716–724. DOIEstablishes the pharmacokinetic rationale for using combined venlafaxine + ODV exposure as the relevant clinical parameter.
- Howell SR, Husbands GEM, Scatina JA, Sisenwine SF. Metabolic disposition of 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man. Xenobiotica. 1993;23(4):349–359. DOICross-species metabolic disposition study defining urinary excretion profile and metabolite identification.
- Fogelman SM, Schmider J, Venkatakrishnan K, et al. O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology. 1999;20(5):480–490. DOIIn vitro CYP characterisation confirming CYP2D6 as primary pathway to ODV and CYP3A4 role in N-demethylation.